Abstract
A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1001-1003 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 64 |
| Issue number | 8-9 |
| State | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors. / Miller, Thomas P; Jones, S. E.; Chester, A.
In: Cancer Treatment Reports, Vol. 64, No. 8-9, 1980, p. 1001-1003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors
AU - Miller, Thomas P
AU - Jones, S. E.
AU - Chester, A.
PY - 1980
Y1 - 1980
N2 - A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.
AB - A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.
UR - http://www.scopus.com/inward/record.url?scp=0019254053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019254053&partnerID=8YFLogxK
M3 - Article
C2 - 7448818
AN - SCOPUS:0019254053
VL - 64
SP - 1001
EP - 1003
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 8-9
ER -